We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
SRP14 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average pTPM
330.5
Number of samples
141
Samples
Sample
Description
pTPM
TCGA-28-5220-01A
67 years, male, white, stage:'--, dead, 388 days
759.8
TCGA-06-5859-01A
63 years, male, white, stage:'--, alive, 139 days
651.9
TCGA-06-1804-01A
81 years, female, white, stage:'--, dead, 414 days
638.9
TCGA-06-2567-01A
65 years, male, white, stage:'--, dead, 133 days
594.0
TCGA-14-1829-01A
57 years, male, black or african american, stage:'--, alive, 218 days
593.4
TCGA-06-5411-01A
51 years, male, white, stage:'--, dead, 254 days
553.9
TCGA-28-2509-01A
77 years, female, white, stage:'--, alive, 145 days
547.0
TCGA-28-5207-01A
71 years, male, white, stage:'--, dead, 343 days
539.7
TCGA-14-2554-01A
52 years, female, white, stage:'--, dead, 532 days
539.3
TCGA-06-5408-01A
54 years, female, white, stage:'--, dead, 357 days
533.6
TCGA-06-0184-01A
63 years, male, white, stage:'--, dead, 2126 days
497.7
TCGA-06-0219-01A
67 years, male, white, stage:'--, dead, 22 days
459.0
TCGA-32-5222-01A
66 years, male, white, stage:'--, dead, 585 days
454.3
TCGA-28-5204-01A
72 years, male, white, stage:'--, dead, 454 days
451.1
TCGA-19-2620-01A
70 years, male, white, stage:'--, dead, 148 days
449.9
TCGA-28-5208-01A
52 years, male, white, stage:'--, dead, 544 days
448.4
TCGA-27-2526-01A
79 years, female, white, stage:'--, dead, 87 days
443.0
TCGA-14-1823-01A
58 years, female, white, stage:'--, dead, 543 days
441.9
TCGA-06-5417-01A
45 years, female, white, stage:'--, alive, 155 days
439.2
TCGA-12-5295-01A
60 years, female, white, stage:'--, dead, 454 days
437.7
TCGA-06-5856-01A
58 years, male, white, stage:'--, dead, 114 days
434.9
TCGA-27-1832-01A
59 years, female, white, stage:'--, dead, 300 days
432.2
TCGA-06-5410-01A
72 years, female, white, stage:'--, dead, 108 days
429.8
TCGA-14-1034-01A
60 years, female, stage:'--, dead, 485 days
429.1
TCGA-06-0749-01A
50 years, male, black or african american, stage:'--, dead, 82 days
424.5
TCGA-12-0616-01A
36 years, female, white, stage:'--, dead, 448 days
418.5
TCGA-26-5139-01A
65 years, female, white, stage:'--, alive, 48 days
411.8
TCGA-76-4929-01A
76 years, female, white, stage:'--, dead, 111 days
411.5
TCGA-06-0750-01A
43 years, male, white, stage:'--, dead, 28 days
409.5
TCGA-06-0882-01A
30 years, male, white, stage:'--, dead, 632 days
404.9
TCGA-32-1980-01A
72 years, male, white, stage:'--, dead, 36 days
394.9
TCGA-06-5858-01A
45 years, female, white, stage:'--, alive, 187 days
394.2
TCGA-15-1444-01A
21 years, male, white, stage:'--, dead, 1537 days
384.9
TCGA-28-1753-01A
53 years, male, white, stage:'--, alive, 37 days
382.3
TCGA-26-5132-01A
74 years, male, white, stage:'--, alive, 286 days
380.1
TCGA-06-0178-01A
38 years, male, white, stage:'--, dead, 2681 days
377.2
TCGA-27-2521-01A
34 years, male, white, stage:'--, dead, 510 days
376.6
TCGA-02-0055-01A
62 years, female, white, stage:'--, dead, 76 days
376.2
TCGA-06-5412-01A
78 years, female, white, stage:'--, dead, 138 days
375.6
TCGA-19-2624-01A
51 years, male, white, stage:'--, dead, 5 days
375.4
TCGA-06-0130-01A
54 years, male, white, stage:'--, dead, 394 days
374.5
TCGA-41-4097-01A
63 years, female, white, stage:'--, dead, 6 days
373.5
TCGA-32-2615-01A
62 years, male, white, stage:'--, dead, 485 days
373.0
TCGA-28-5216-01A
52 years, male, white, stage:'--, alive, 415 days
368.1
TCGA-02-2485-01A
53 years, male, black or african american, stage:'--, alive, 470 days
365.7
TCGA-02-2486-01A
64 years, male, white, stage:'--, dead, 618 days
362.2
TCGA-06-0138-01A
43 years, male, white, stage:'--, dead, 737 days
357.4
TCGA-19-2625-01A
76 years, female, white, stage:'--, dead, 124 days
356.7
TCGA-12-3652-01A
60 years, male, white, stage:'--, dead, 1062 days
355.7
TCGA-32-2632-01A
80 years, male, white, stage:'--, dead, 269 days
353.2
TCGA-12-5299-01A
56 years, female, white, stage:'--, dead, 98 days
352.8
TCGA-28-5209-01A
66 years, female, white, stage:'--, alive, 442 days
352.3
TCGA-26-5134-01A
74 years, male, white, stage:'--, alive, 167 days
347.8
TCGA-15-0742-01A
65 years, male, white, stage:'--, dead, 419 days
346.7
TCGA-06-5413-01A
67 years, male, white, stage:'--, alive, 268 days
343.3
TCGA-14-0787-01A
69 years, male, asian, stage:'--, dead, 68 days
341.6
TCGA-06-2565-01A
59 years, male, asian, stage:'--, dead, 506 days
341.0
TCGA-06-0747-01A
53 years, male, white, stage:'--, dead, 82 days
339.9
TCGA-32-1982-01A
76 years, female, white, stage:'--, dead, 142 days
338.9
TCGA-06-0168-01A
59 years, female, white, stage:'--, dead, 598 days
338.5
TCGA-06-2564-01A
50 years, male, white, stage:'--, alive, 181 days
337.9
TCGA-76-4927-01A
58 years, male, white, stage:'--, dead, 535 days
336.8
TCGA-27-1831-01A
66 years, male, white, stage:'--, dead, 505 days
334.6
TCGA-06-0132-01A
49 years, male, white, stage:'--, dead, 771 days
332.7
TCGA-27-2528-01A
62 years, male, white, stage:'--, dead, 480 days
332.2
TCGA-06-0158-01A
73 years, male, white, stage:'--, dead, 329 days
332.2
TCGA-08-0386-01A
74 years, male, white, stage:'--, dead, 548 days
329.1
TCGA-06-0878-01A
74 years, male, white, stage:'--, alive, 218 days
325.0
TCGA-28-5218-01A
63 years, male, white, stage:'--, dead, 157 days
317.8
TCGA-32-1970-01A
59 years, male, white, stage:'--, dead, 468 days
316.7
TCGA-12-3653-01A
34 years, female, white, stage:'--, dead, 442 days
316.3
TCGA-26-1442-01A
43 years, male, white, stage:'--, alive, 953 days
314.5
TCGA-14-0817-01A
69 years, female, white, stage:'--, dead, 164 days
314.2
TCGA-06-2563-01A
72 years, female, white, stage:'--, alive, 932 days
313.6
TCGA-19-2619-01A
55 years, female, black or african american, stage:'--, alive, 294 days
312.1
TCGA-06-5414-01A
61 years, male, white, stage:'--, alive, 273 days
310.0
TCGA-32-2634-01A
82 years, male, white, stage:'--, alive, 693 days
307.0
TCGA-06-2561-01A
53 years, female, white, stage:'--, dead, 537 days
301.9
TCGA-06-0644-01A
71 years, male, black or african american, stage:'--, dead, 384 days
301.4
TCGA-06-0156-01A
57 years, male, white, stage:'--, dead, 178 days
301.3
TCGA-02-2483-01A
43 years, male, asian, stage:'--, alive, 466 days
301.1
TCGA-76-4931-01A
70 years, female, white, stage:'--, dead, 279 days
300.1
TCGA-76-4932-01A
50 years, female, white, stage:'--, dead, 1458 days
297.3
TCGA-06-2570-01A
21 years, female, white, stage:'--, alive, 958 days
297.0
TCGA-19-5960-01A
56 years, male, white, stage:'--, dead, 455 days
297.0
TCGA-14-1825-01A
70 years, male, white, stage:'--, dead, 232 days
295.1
TCGA-28-5215-01A
62 years, female, white, stage:'--, dead, 335 days
293.6
TCGA-06-0139-01A
40 years, male, white, stage:'--, dead, 362 days
292.8
TCGA-32-2638-01A
67 years, male, white, stage:'--, dead, 766 days
290.1
TCGA-06-0744-01A
66 years, male, white, stage:'--, dead, 1426 days
289.3
TCGA-06-0157-01A
63 years, female, white, stage:'--, dead, 97 days
278.0
TCGA-27-2523-01A
63 years, male, white, stage:'--, dead, 489 days
277.7
TCGA-06-5418-01A
75 years, female, white, stage:'--, dead, 83 days
277.7
TCGA-06-0743-01A
69 years, male, white, stage:'--, dead, 803 days
271.9
TCGA-26-5133-01A
59 years, male, white, stage:'--, alive, 452 days
270.7
TCGA-06-0238-01A
46 years, male, white, stage:'--, dead, 405 days
267.8
TCGA-27-1835-01A
53 years, female, white, stage:'--, dead, 648 days
267.2
TCGA-06-2569-01A
24 years, female, black or african american, stage:'--, alive, 13 days
266.4
TCGA-06-0129-01A
30 years, male, asian, stage:'--, dead, 1024 days
265.7
TCGA-41-3915-01A
48 years, male, white, stage:'--, dead, 360 days
263.4
TCGA-41-2572-01A
67 years, male, white, stage:'--, dead, 406 days
263.0
TCGA-27-1837-01A
36 years, male, white, stage:'--, dead, 427 days
262.7
TCGA-06-2558-01A
75 years, female, white, stage:'--, dead, 380 days
257.9
TCGA-32-4213-01A
47 years, female, white, stage:'--, alive, 604 days
254.0
TCGA-14-0789-01A
54 years, male, white, stage:'--, dead, 342 days
253.6
TCGA-06-2557-01A
76 years, male, black or african american, stage:'--, dead, 33 days
253.6
TCGA-06-0187-01A
69 years, male, white, stage:'--, dead, 828 days
252.5
TCGA-06-0141-01A
62 years, male, white, stage:'--, dead, 313 days
251.8
TCGA-12-3650-01A
46 years, male, white, stage:'--, dead, 333 days
250.3
TCGA-06-2559-01A
83 years, male, white, stage:'--, dead, 150 days
247.1
TCGA-19-1390-01A
63 years, female, white, stage:'--, dead, 772 days
245.0
TCGA-14-0871-01A
74 years, female, white, stage:'--, dead, 880 days
243.8
TCGA-06-0645-01A
55 years, female, white, stage:'--, dead, 175 days
242.7
TCGA-06-0210-01A
72 years, female, white, stage:'--, dead, 225 days
242.0
TCGA-19-2629-01A
60 years, male, white, stage:'--, dead, 737 days
241.0
TCGA-12-0821-01A
62 years, male, white, stage:'--, dead, 323 days
236.3
TCGA-06-5416-01A
23 years, female, white, stage:'--, alive, 204 days
232.7
TCGA-02-0047-01A
78 years, male, white, stage:'--, dead, 448 days
228.2
TCGA-26-5135-01A
72 years, female, white, stage:'--, dead, 270 days
226.7
TCGA-06-0174-01A
54 years, male, white, stage:'--, dead, 98 days
225.9
TCGA-27-2524-01A
56 years, male, white, stage:'--, dead, 231 days
225.8
TCGA-16-0846-01A
85 years, male, white, stage:'--, dead, 119 days
219.5
TCGA-27-2519-01A
48 years, male, white, stage:'--, dead, 550 days
211.5
TCGA-06-0125-01A
63 years, female, white, stage:'--, dead, 1448 days
211.0
TCGA-06-0211-01A
47 years, male, white, stage:'--, dead, 360 days
209.5
TCGA-28-2514-01A
45 years, male, asian, stage:'--, alive, 160 days
207.5
TCGA-06-0646-01A
60 years, male, white, stage:'--, dead, 175 days
206.8
TCGA-27-1834-01A
56 years, male, white, stage:'--, dead, 1233 days
203.5
TCGA-06-0745-01A
59 years, male, white, stage:'--, dead, 239 days
195.2
TCGA-41-2571-01A
89 years, male, white, stage:'--, dead, 26 days
191.4
TCGA-76-4925-01A
76 years, male, white, stage:'--, dead, 146 days
190.7
TCGA-27-1830-01A
57 years, male, white, stage:'--, dead, 154 days
189.8
TCGA-19-4065-01A
36 years, male, white, stage:'--, alive, 214 days
189.3
TCGA-06-0686-01A
53 years, male, white, stage:'--, dead, 432 days
188.6
TCGA-28-2513-01A
69 years, female, white, stage:'--, alive, 222 days
187.4
TCGA-41-5651-01A
59 years, female, black or african american, stage:'--, dead, 460 days
185.8
TCGA-32-2616-01A
48 years, female, white, stage:'--, dead, 224 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
SRP14 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average pTPM
265.0
Number of samples
58
Samples
Sample
Description
pTPM
AK041
N, NA, stage:NA, alive, 810 days
406.5
AK216
N, NA, stage:NA, dead, 360 days
401.6
AK139
N, NA, stage:NA, dead, 270 days
398.1
AK066
N, NA, stage:NA, alive, 960 days
382.5
AK035
N, NA, stage:NA, dead, 210 days
375.9
AK231
N, NA, stage:NA, dead, 240 days
369.9
AK236
N, NA, stage:NA, dead, 360 days
356.9
AK030
N, NA, stage:NA, dead, 120 days
350.7
AK134
N, NA, stage:NA, dead, 360 days
343.9
AK068
N, NA, stage:NA, alive, 360 days
334.5
AK099
N, NA, stage:NA, dead, 420 days
332.5
AK043
N, NA, stage:NA, alive, 660 days
326.2
AK100
N, NA, stage:NA, alive, 960 days
325.3
AK227
N, NA, stage:NA, alive, 300 days
319.7
AK071
N, NA, stage:NA, dead, 540 days
316.3
AK055
N, NA, stage:NA, dead, 240 days
302.1
AK117
N, NA, stage:NA, dead, 210 days
295.4
AK199
N, NA, stage:NA, alive, 1860 days
293.7
AK158
N, NA, stage:NA, dead, 360 days
293.7
AK005
N, NA, stage:NA, dead, 240 days
293.6
AK002
N, NA, stage:NA, dead, 570 days
283.2
AK213
N, NA, stage:NA, alive, 2010 days
282.7
AK098
N, NA, stage:NA, dead, 660 days
280.6
AK133
N, NA, stage:NA, dead, 360 days
278.9
AK153
N, NA, stage:NA, dead, 240 days
277.6
AK167
N, NA, stage:NA, dead, 180 days
277.0
AK074
N, NA, stage:NA, alive, 300 days
271.1
AK081
N, NA, stage:NA, dead, 180 days
267.2
AK088
N, NA, stage:NA, dead, 360 days
266.3
AK226
N, NA, stage:NA, dead, 360 days
265.9
AK218
N, NA, stage:NA, dead, 180 days
265.6
AK173
N, NA, stage:NA, dead, 180 days
260.9
AK015
N, NA, stage:NA, alive, 720 days
254.8
AK124
N, NA, stage:NA, alive, 1920 days
254.6
AK188
N, NA, stage:NA, alive, 420 days
252.6
AK195
N, NA, stage:NA, dead, 390 days
250.7
AK085
N, NA, stage:NA, alive, 660 days
246.9
AK178
N, NA, stage:NA, dead, 240 days
239.0
AK076
N, NA, stage:NA, alive, 660 days
233.5
AK205
N, NA, stage:NA, dead, 120 days
232.1
AK079
N, NA, stage:NA, dead, 210 days
231.7
AK185
N, NA, stage:NA, alive, 330 days
226.1
AK089
N, NA, stage:NA, dead, 330 days
225.3
AK149
N, NA, stage:NA, dead, 420 days
224.2
AK072
N, NA, stage:NA, dead, 150 days
202.3
AK183
N, NA, stage:NA, alive, 360 days
200.4
AK142
N, NA, stage:NA, alive, 90 days
195.9
AK051
N, NA, stage:NA, dead, 360 days
193.2
AK103
N, NA, stage:NA, alive, 1320 days
186.8
AK003
N, NA, stage:NA, dead, 600 days
182.5
AK102
N, NA, stage:NA, alive, 1740 days
178.1
AK123
N, NA, stage:NA, dead, 180 days
177.7
AK156
N, NA, stage:NA, dead, 330 days
168.0
AK006
N, NA, stage:NA, dead, 360 days
166.8
AK091
N, NA, stage:NA, dead, 210 days
165.0
AK053
N, NA, stage:NA, dead, 300 days
138.2
AK049
N, NA, stage:NA, dead, 180 days
125.8
AK165
N, NA, stage:NA, alive, 360 days
125.6
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0078580003
Tumor
1.1
CPT0217190003
Tumor
0.9
CPT0168080003
Tumor
0.7
CPT0162140003
Tumor
0.6
CPT0218770003
Tumor
0.6
CPT0206780003
Tumor
0.5
CPT0201710003
Tumor
0.5
CPT0217710008
Tumor
0.5
CPT0161730003
Tumor
0.5
CPT0189570004
Tumor
0.5
CPT0208980003
Tumor
0.5
CPT0087680003
Tumor
0.4
CPT0206670004
Tumor
0.4
CPT0206560003
Tumor
0.4
CPT0093450003
Tumor
0.4
CPT0190240004
Tumor
0.4
CPT0218830004
Tumor
0.4
CPT0207090003
Tumor
0.4
CPT0127480003
Tumor
0.4
CPT0217430008
Tumor
0.3
CPT0206230003
Tumor
0.3
CPT0217100003
Tumor
0.3
CPT0182500003
Tumor
0.3
CPT0218330004
Tumor
0.3
CPT0224390004
Tumor
0.3
CPT0167530003
Tumor
0.3
CPT0217000004
Tumor
0.3
CPT0218690004
Tumor
0.3
CPT0205780003
Tumor
0.2
CPT0071100003
Tumor
0.2
CPT0218890004
Tumor
0.2
CPT0182550003
Tumor
0.2
CPT0218670003
Tumor
0.2
CPT0167640003
Tumor
0.2
CPT0189750004
Tumor
0.2
CPT0167750004
Tumor
0.2
CPT0125570003
Tumor
0.2
CPT0225730003
Tumor
0.1
CPT0171580008
Tumor
0.1
CPT0206000004
Tumor
0.1
CPT0168270003
Tumor
0.1
CPT0182580003
Tumor
0.1
CPT0125220003
Tumor
0.1
CPT0167970003
Tumor
0.1
CPT0219080004
Tumor
0.1
CPT0205570003
Tumor
0.1
CPT0221180003
Tumor
0.1
CPT0224540004
Tumor
0.1
CPT0218960004
Tumor
0.0
CPT0168830003
Tumor
0.0
CPT0189460003
Tumor
0.0
CPT0224600003
Tumor
0.0
CPT0064890003
Tumor
0.0
CPT0189250003
Tumor
0.0
CPT0127420003
Tumor
0.0
CPT0205670004
Tumor
0.0
CPT0224330003
Tumor
0.0
CPT0125510003
Tumor
0.0
CPT0104330003
Tumor
0.0
CPT0216920008
Tumor
0.0
CPT0162100003
Tumor
0.0
CPT0175060003
Tumor
0.0
CPT0002410011
Tumor
-0.1
CPT0093510003
Tumor
-0.1
CPT0205890003
Tumor
-0.1
CPT0123530003
Tumor
-0.1
CPT0204330003
Normal
-0.1
CPT0225760003
Tumor
-0.1
CPT0217880003
Tumor
-0.1
CPT0189850004
Tumor
-0.1
CPT0092440003
Tumor
-0.1
CPT0217060003
Tumor
-0.1
CPT0207030003
Tumor
-0.1
CPT0087570003
Tumor
-0.1
CPT0168480003
Tumor
-0.1
CPT0205450004
Tumor
-0.2
CPT0190360004
Tumor
-0.2
CPT0168380003
Tumor
-0.2
CPT0204370003
Normal
-0.2
CPT0228220003
Tumor
-0.2
CPT0209440003
Tumor
-0.2
CPT0204380003
Normal
-0.2
CPT0093360003
Tumor
-0.2
CPT0093550003
Tumor
-0.2
CPT0204390003
Normal
-0.2
CPT0064650003
Tumor
-0.3
CPT0204420003
Normal
-0.3
CPT0199770003
Tumor
-0.3
CPT0206110003
Tumor
-0.3
CPT0186100003
Tumor
-0.3
CPT0089150003
Tumor
-0.3
CPT0168720003
Tumor
-0.3
CPT0204400003
Normal
-0.3
CPT0168590003
Tumor
-0.3
CPT0079790003
Tumor
-0.4
CPT0204350003
Normal
-0.4
CPT0206330003
Tumor
-0.4
CPT0206880003
Tumor
-0.4
CPT0206450003
Tumor
-0.4
CPT0104220003
Tumor
-0.4
CPT0162020003
Tumor
-0.4
CPT0087950003
Tumor
-0.4
CPT0204340003
Normal
-0.4
CPT0093590003
Tumor
-0.4
CPT0204410003
Normal
-0.4
CPT0196850003
Tumor
-0.5
CPT0167860004
Tumor
-0.5
CPT0204360003
Normal
-0.5
CPT0087730003
Tumor
-0.5
CPT0189650004
Tumor
-0.8
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.